CLIENT LOGIN

ORDER GUARDANT360

clientservices@guardanthealth.com

855-698-8887

MEDICAL PROFESSIONALS

PATIENTS

Through a simple blood draw, Guardant360™ analyzes a patient’s current cancer genomics in order to better inform treatment decisions - all without a biopsy.

HOW IT WORKS

SUBMIT 2 TUBES OF BLOOD

WE SEQUENCE A PATIENT'S CANCER ACROSS DOZENS OF GENES

WE IDENTIFY GENOMIC ALTERATIONS AND ASSOCIATED TREATMENT OPTIONS

EVERY REPORT IS REVIEWED BY GUARDANT'S MOLECULAR TUMOR BOARD

TEST RESULTS PROVIDED WITHIN 2 WEEKS OF KIT RECEIPT

FOR MEDICAL PROFESSIONALS

FOR PATIENTS

How often do you wish you knew more about your patient’s cancer, but can’t afford the time, cost, or risk
of additional biopsies once you’ve begun treatment? Guardant360™ acts as a complement to traditional biopsies by reconstructing and sequencing a patient’s current cancer using tumor-derived DNA – all via a simple blood draw. We generate a report of each patient’s genomic alterations and provide detailed, supporting information to aid in therapy selection
that helps manage cancer in real-time.

From the moment you are diagnosed with cancer it
is hard to find peace of mind. You constantly wonder if your cancer is growing and whether treatments
are working.  Only Guardant360™ gives an in-depth genomic view of your cancer in real time.  This cost effective, simple blood test provides unparalleled insight and enables your physician to better personalize your treatment options.

SIMPLE BLOOD TEST.

DEEP CANCER INSIGHTS.
REAL-TIME
 ANSWERS.

PLAY VIDEO

 

Guardant360™ has undergone clinical validation in collaboration with leading cancer centers in the United States and abroad, and is currently being used for companion diagnostics in clinical studies of molecularly targeted drug therapies. Click here to read related academic papers or click here to read recent articles about Guardant Health.

 

About Us

Share This

Links

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital and Khosla Ventures, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.





© 2014 GUARDANT HEALTH, INC.  ALL RIGHTS RESERVED.

LEGAL / PRIVACY